Drug Profile
Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical
Alternative Names: Ceragenins; CGX-313; CSA 90; CSA-13; CSA-131; CSA-54; CSA-8; CSAsLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Brigham Young University
- Developer Brigham Young University; Ceragenix Pharmaceuticals; N8 Medical
- Class Anti-infectives; Antibacterials; Antifungals; Antivirals; Small molecules; Steroids
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections; Fracture
- Discontinued Methicillin-resistant Staphylococcus aureus infections; Vaccinia; Viral infections
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Topical)
- 28 Jan 2021 Preclinical development for Bacterial infections is ongoing in USA (Topical, PO)